About Scholar Rock
Scholar Rock is a publicly listed company based in Cambridge (United States) founded in 2012. Antibody-based drugs for primary myopathies are developed and targeted. Scholar Rock has raised $103.3 million across 4 funding rounds from investors including Fidelity Investments, Arch Venture Partners and Invus. The company has 196 employees. Its chief executive, as recorded, is Nagesh Mahanthappa. Its website scholarrock.com draws about 12 thousand monthly visits. Scholar Rock offers products and services including Therapies for Spinal Muscular Atrophy and Therapies for Cancer. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting. Its legal entity is Scholar Rock, Inc. Its competitors include Kriya Therapeutics, Sana Biotechnology and PureTech Health; 3 of its 3 listed competitors have raised funding.
Company details
Scholar Rock was founded in 2012 in Cambridge, United States, within the biotechnology sector. Niche modulators, a class of biologic therapies, are discovered and developed to selectively target dysregulated growth factors in disease microenvironments, particularly members of the TGFβ superfamily. These therapies address conditions such as fibrosis, musculoskeletal disorders, and autoimmune diseases. Operations focus on antibody-based inhibitors like SRK-015, a monoclonal antibody for latent myostatin activation in primary myopathies.
- Headquarters Cambridge, United States
- Employees 196
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website scholarrock.com
- Social LinkedIn X
- Legal Name Scholar Rock Holding Corporation
- Net Profit-$377.94 M (USD)-53.45as on Dec 31, 2025
- EBITDA-$382.99 M (USD)-53.12as on Dec 31, 2025
- Total Equity Funding$103.3M (USD)
in 4 rounds
- Latest Funding Round$205M (USD), Post-IPO
Jun 2022
- InvestorsFidelity Investments
& 7 more
- Employee Count196
Products & Services of Scholar Rock
Scholar Rock offers a comprehensive portfolio of products and services, including Therapies for Spinal Muscular Atrophy and Therapies for Cancer.
Investigational treatments targeting growth factors for SMA
Drugs for solid tumors via selective protein inhibition
Funding Insights of Scholar Rock
Scholar Rock has successfully raised a total of $103.3M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $205 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $103.3M
- Total Rounds 4
- Last Round Post-IPO β $205M
- First Round $20M
(Sep 2014)
- Investors Count 8
All 4 funding rounds of Scholar Rock with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2022 | $205M | Post-IPO | β | β | β |
| Jan 2018 | $47M | Series C | β | Invus | |
| Jan 2016 | $36.3M | Series B | β | Fidelity Investments | |
| Sep 2014 | $20M | Series A | β | β |
8 investors in total: 7 institutional and 1 angel.
Investors in Scholar Rock
Scholar Rock has secured backing from 8 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Fidelity Investments, Arch Venture Partners and Invus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States | ||
US focused venture capital firm | polarispartners.com | Boston, United States | ||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Investments and family assets are managed by The Kraft Group. | thekraftgroup.com | Foxborough, United States | ||
Operates as an employee-owned hedge fund focused on long/short equity strategies. | 2007 | redmilegroup.com | San Francisco, United States | |
| ecor1cap.com | ||||
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States | |
TS Timothy Springer | unknown_475180bf8fa945519 |
Investor details for Scholar Rock
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Scholar Rock
125 people are tracked at Scholar Rock (69 in leadership, 8 in board & advisors, 48 in team); the tracked headcount is 196.
| Name | Role | Group |
|---|---|---|
Nagesh Mahanthappa | Founding CEO & President | Leadership |
Ilia A. | Vp, Head Of Global Scientific Communications And Medical Excellence | Leadership |
Scott Adamczyk | Senior Vice President, Head Of Regulatory | Leadership |
Mohammad Sahtout | Associate Director, Biostatistics | Leadership |
Jay Backstrom | President & CEO | Leadership |
Caryn Parlavecchio | Chief Human Resources Officer | Leadership |
Kimberley Caliri | Senior Director, Clinical Operations | Leadership |
Jing Marantz | Chief Medical Officer | Leadership |
Laura Ekas | Vice President, Investor Relations | Leadership |
Jason Donnelly | Vice President, Quality Assurance | Leadership |
Diane Damadio | Director Of Marketing Operations | Leadership |
Linda Bates | Associate Director, Medical Writing | Leadership |
Stephanie Howard, MS, ATC | Associate Director, Clinical Operations | Leadership |
Lisa Wyman | Chief Technical & Quality Officer | Leadership |
Jennifer B. | Sr. Director, Clinical Science And Translational Dev./ Clinical Program Lead, Cardiometabolic | Leadership |
Jared Tur | Associate Director, Medical Writing [nonclinical] | Leadership |
Dongzi Yu | Medical Director | Leadership |
Susan H. | Senior Director, Translational Sciences | Leadership |
Shaun Cote | Associate Director | Leadership |
Yawen Ju | Director Clinical Scientist | Leadership |
105 more people are available in the full profile.
Complete people profiles for Scholar Rock
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Scholar Rock
Scholar Rock is a publicly listed company on the NASDAQ with ticker symbol SRRK in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date24 May 2018
- Listed onNASDAQ: SRRK · NYSE: SRRK
- Listed entityScholar Rock Holding Corporation
- Exchange sectorHealth technology
- ISINUS80706P1030
- Share price$40.52 (-3.39% on the day) · 2026-10-13
- Market capitalisation$4.93B
- EPS (diluted, trailing year)$-3.45
- Volume (last session)1,096,269
Financials of Scholar Rock
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$377.9M | -$383.0M | |
| 2024 | -$246.3M | -$250.1M | |
| 2023 | -$165.8M | -$168.4M | |
| 2022 | $33.2M | -$134.5M | -$124.5M |
| 2021 | $18.8M | -$131.8M | -$120.9M |
Detailed financial statements for Scholar Rock
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Scholar Rock
4 dated milestones of Scholar Rock across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Scholar Rock is founded.
- Funding First funding round of $20.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $205.0M.
Competitors of Scholar Rock
Scholar Rock has 3 listed competitors in our database, 3 of them funded. They include Kriya Therapeutics, Sana Biotechnology and PureTech Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. |
Detailed competitors of Scholar Rock
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Scholar Rock
The website of Scholar Rock (scholarrock.com) receives about 11.7K visits a month and ranks #1,646,973 among all websites worldwide, #2,215 in Biotechnology and Pharmaceuticals.
- Monthly visits11.7K
▼ 11.8% vs previous month
- Unique visitors5.6K
per month
- Global rank#1,646,973
among all websites
- Category rank#2,215
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit2.4
- Average visit16 sec
- DevicesDesktop 40% Β· Mobile 60%
Websites whose visitors overlap most with Scholar Rock. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| formatherapeutics.com | 100% | View details | |||
| smanewstoday.com | 74% | #1,707,465 | View details | ||
| fiercebiotech.com | 71% | 858.3K | #81,022 | View details | |
ce4nurses.org | ce4nurses.org | 55% | β | ||
| biomet.com | 54% | 1.7K | #10,154,264 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 7 similar websites and full traffic analytics for Scholar Rock
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Scholar Rock (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Scholar Rock
Complete news archive for Scholar Rock
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Scholar Rock
Scholar Rock was founded in 2012 and raised its 1st funding round 2 years after it was founded.
Scholar Rock is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Nagesh Mahanthappa is the CEO of Scholar Rock, as recorded in our data.
Scholar Rock is a funded company, having raised a total of $103.3M across 4 funding rounds to date. The company's 1st funding round was a Series A of $20M, raised on Sep 2014.
Scholar Rock has 196 employees.
Scholar Rock was founded in 2012 in Cambridge, United States, within the biotechnology sector. Niche modulators, a class of biologic therapies, are discovered and developed to selectively target dysregulated growth factors in disease microenvironments, particularly members of the TGFΞ² superfamily. These therapies address conditions such as fibrosis, musculoskeletal disorders, and autoimmune diseases. Operations focus on antibody-based inhibitors like SRK-015, a monoclonal antibody for latent myostatin activation in primary myopathies.
Scholar Rock's top competitors include Sana Biotechnology, PureTech Health and Kriya Therapeutics.
Scholar Rock offers Therapies for Spinal Muscular Atrophy and Therapies for Cancer.
Yes, Scholar Rock is publicly traded on NASDAQ under the ticker symbol SRRK.
Scholar Rock has 8 investors. Key investors include Fidelity Investments, Arch Venture Partners, Invus, Redmile Group, and Polaris Partners.
Scholar Rock operates through Scholar Rock, Inc..